The New Jersey District Court has converted a temporary injuction into a preliminary injuction against Dr Reddy, on sale of a generic version of Indivior’s prescription medicine Suboxone in the US market. The drug is used for treatment of opioid dependence.
The court has restricted Dr Redyy from re-launching its generic product, until the patent litigation by Indivior is concluded until it prevails on an appeal of this injunction.
Further, the court has also ordered the parties to submit a final proposed injunction order on Monday. It has asked Indivior to post a bond to provide security to Dr Reddy’s should the court conclude at the end of patent litigation that the patent is invalid or not infringed.